Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Ironwood Pharmaceuticals (IRWD) FCF Margin (2016 - 2025)

Ironwood Pharmaceuticals' FCF Margin history spans 16 years, with the latest figure at 156.31% for Q4 2025.

  • For Q4 2025, FCF Margin rose 13951.0% year-over-year to 156.31%; the TTM value through Dec 2025 reached 42.89%, up 1346.0%, while the annual FY2025 figure was 42.89%, 1346.0% up from the prior year.
  • FCF Margin for Q4 2025 was 156.31% at Ironwood Pharmaceuticals, up from 38.98% in the prior quarter.
  • Across five years, FCF Margin topped out at 156.31% in Q4 2025 and bottomed at 17.68% in Q2 2025.
  • The 5-year median for FCF Margin is 51.72% (2021), against an average of 52.03%.
  • The largest YoY upside for FCF Margin was 13951bps in 2025 against a maximum downside of -5307bps in 2025.
  • A 5-year view of FCF Margin shows it stood at 55.02% in 2021, then soared by 34bps to 73.89% in 2022, then crashed by -59bps to 30.3% in 2023, then crashed by -45bps to 16.8% in 2024, then soared by 830bps to 156.31% in 2025.
  • Per Business Quant, the three most recent readings for IRWD's FCF Margin are 156.31% (Q4 2025), 38.98% (Q3 2025), and 17.68% (Q2 2025).